Potent and selective 5-HT4
partial agonist (EC50
= 0.927 nM). Displays > 1000-fold selectivity for 5-HT4
over other 5-HT and D2
receptors. Exhibits gastroprokinetic effects in vivo
following oral administration. Weakly blocks hERG (IC50
= 2.6 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The 5-HT4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities.
Toga et al.
5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-α]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroproki
Mikami et al.